Josep Font

Active 1982–2021

96
Papers
20,875
Citations
82
h-index
95
i10-index

Citations

Citations per year for Josep Font1983: 3 citations1984: 1 citations1989: 1 citations1990: 1 citations1991: 7 citations1992: 9 citations1993: 5 citations1994: 15 citations1995: 4 citations1996: 22 citations1997: 16 citations1998: 19 citations1999: 34 citations2000: 35 citations2001: 52 citations2002: 80 citations2003: 97 citations2004: 107 citations2005: 156 citations2006: 132 citations2007: 154 citations2008: 126 citations2009: 169 citations2010: 152 citations2011: 161 citations2012: 158 citations2013: 132 citations2014: 158 citations2015: 135 citations2016: 154 citations2017: 126 citations2018: 115 citations2019: 385 citations2020: 377 citations2021: 343 citations2022: 251 citations2023: 139 citations2024: 242 citations2025: 83 citations2026: 2 citations1985–1988: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,082 citing papers, 18.7% of this breakdownItaly: 427 citing papers, 7.4% of this breakdownUnited Kingdom: 404 citing papers, 7% of this breakdownSpain: 388 citing papers, 6.7% of this breakdownFrance: 315 citing papers, 5.5% of this breakdownChina: 297 citing papers, 5.1% of this breakdownCanada: 229 citing papers, 4% of this breakdownGermany: 184 citing papers, 3.2% of this breakdownNetherlands: 164 citing papers, 2.8% of this breakdownGreece: 162 citing papers, 2.8% of this breakdownSweden: 131 citing papers, 2.3% of this breakdownAustralia: 125 citing papers, 2.2% of this breakdown
0%18.7%Other 32.3%

Fields

  • Medicine82.8%
  • Biochemistry, Genetics and Molecular Biology7.3%
  • Immunology and Microbiology3.9%
  • Engineering1.7%
  • Neuroscience1%
  • Environmental Science0.9%
  • Other2.4%

Topics

  • Systemic Lupus Erythematosus Research20%
  • Systemic Sclerosis and Related Diseases3.8%
  • Rheumatoid Arthritis Research and Therapies3.3%
  • Salivary Gland Disorders and Functions2.9%
  • Liver Diseases and Immunity2.8%
  • Platelet Disorders and Treatments2.6%
  • Other64.6%

Coauthors

All papers

Open in search
  1. Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Arthritis & Rheumatism 2002 cited by 2,154

  2. Morbidity and Mortality in Systemic Lupus Erythematosus During a 10-Year Period

    Authors: , , , , , , , , , , , , , , , , , , , - Medicine 2003 cited by 1,385

  3. Immunosuppressive therapy in lupus nephritis: The Euro‐Lupus Nephritis Trial, a randomized trial of low‐dose versus high‐dose intravenous cyclophosphamide

    Authors: , , , , , , , , , , , , , , , , , , , , , - Arthritis & Rheumatism 2002 cited by 1,071

  4. Targeting glutamine transport to suppress melanoma cell growth

    Authors: , , , , , , , , , , , , - International Journal of Cancer 2014 cited by 218

  5. Systemic Lupus Erythematosus

    Authors: , , , , , , , , , , , , , , , - Medicine 1993 cited by 982

  6. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide

    Authors: , , , , , , , , , , , , , , , , , , , , , - Annals of the Rheumatic Diseases 2009 cited by 540

  7. Glutamate transporters have a chloride channel with two hydrophobic gates

    Authors: , , , , , , , , , - Nature 2021 cited by 68

  8. Mortality in the catastrophic antiphospholipid syndrome: Causes of death and prognostic factors in a series of 250 patients

    Authors: , , , , , , , - Arthritis & Rheumatism 2006 cited by 332

  9. The Overlap of Sjögren’s Syndrome with Other Systemic Autoimmune Diseases

    Authors: , , - Seminars in Arthritis and Rheumatism 2006 cited by 151

  10. Structural characterisation reveals insights into substrate recognition by the glutamine transporter ASCT2/SLC1A5

    Authors: , , , , - Nature Communications 2017 cited by 86

  11. Robust Data-Driven Soft Sensors for Online Monitoring of Volatile Fatty Acids in Anaerobic Digestion Processes

    Authors: , , , , - Processes 2020 cited by 68

  12. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics

    Authors: , , , , , , , , , , , , , , , , , , , , - Annals of the Rheumatic Diseases 2007 cited by 757

  13. Infectious origin of the antiphospholipid syndrome

    Authors: , , , , , - Annals of the Rheumatic Diseases 2005 cited by 208

  14. Clusters of clinical and immunologic features in systemic lupus erythematosus: analysis of 600 patients from a single center

    Authors: - Seminars in Arthritis and Rheumatism 2004 cited by 184

  15. A novel recovery process for lipids from microalgæ for biodiesel production using a hydrated phosphonium ionic liquid

    Authors: , , , , , , , , - Green Chemistry 2015 cited by 101

  16. Amino Acid Transporters and Exchangers from the SLC1A Family: Structure, Mechanism and Roles in Physiology and Cancer

    Authors: , , , , , , , - Neurochemical Research 2020 cited by 67

  17. Primary Sjögren Syndrome

    Authors: , , , , , , , - Medicine 2002 cited by 440

  18. Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome

    Authors: , , , , , , , , , , - Annals of the Rheumatic Diseases 2005 cited by 249

  19. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: Lessons from long‐term followup of patients in the Euro‐Lupus Nephritis Trial

    Authors: , , , , , , , , , , , , , , , , , , , , , - Arthritis & Rheumatism 2004 cited by 387

  20. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: An international inception cohort study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Vernon T. Farewell - Arthritis & Rheumatism 2006 cited by 317

  21. Outward- and inward-facing structures of a putative bacterial transition-metal transporter with homology to ferroportin

    Authors: , , , , , , , , - Nature Communications 2015 cited by 122

  22. Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Thomas Stoll, Jill P. Buyon - Lupus 2007 cited by 107

  23. Short‐term outcome of neuropsychiatric events in systemic lupus erythematosus upon enrollment into an international inception cohort study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , K. Qiufen Qi, Kara Thompson, Vernon T. Farewell - Arthritis Care & Research 2008 cited by 106

  24. Catastrophic Antiphospholipid Syndrome: Clinical and Laboratory Features of 50 Patients

    Authors: , , , , , , , , , , , - Medicine 1998 cited by 547